Total 350 words used.
The pharmaceutical industry spends billions of dollars annually on marketing campaigns and patient support programs aimed at guiding healthcare consumers to start and stay on therapy. Unfortunately, research shows that these initiatives are largely unsuccessful, with low therapy initiation and medication non-adherence leading to poor health outcomes and high costs. The reason why: although every patient is unique, the industry has communicated to healthcare consumers monolithically – at best, communicating to segments or personas.
Enter AllazoHealth, the pioneer in delivering AI-driven healthcare experiences. AllazoHealth empowers pharmaceutical organizations to personalize touchpoints and create the optimal experience for each individual, maximizing the impact and efficiency of pharmaceutical marketing and patient support programs.
Unlike technologies that enable rules-based or persona-based targeting, AllazoHealth’s AI securely and compliantly uses identified, patient-level data from both clients’ data sources as well as AllazoHealth’s database of more than 29 million patient records.
Only AllazoHealth delivers truly personalized targeting recommendations based on this identified patient intent data. Leveraging more than 500 predictors about a person, AllazoHealth then provides data-driven decisions that identifies risk factors for every individual patient and drives the optimal channels, content, timing, and cadence for each person, enabling our customers and partners to create truly one-to-one patient health journeys.
Through large datasets and its AI solution, AllazoHealth can help organizations determine the optimal engagement levers for each and every individual patient and drive medication initiation and adherence. At the same time, AllazoHealth’s algorithms continuously learn and improve based on ongoing results so patient programs are optimized.
AllazoHealth’s breakthrough technology currently helps its healthcare customers to improve medication adherence and health outcomes for millions of people across the United States. In fact, AllazoHealth is validated to drive:
- Up to 9% increase in therapy initiation rates,
- 13.3% increase in days on therapy,
- 7% increase in email engagement (open rates)
- Nearly 25% lower spending on operations
Importantly, as demonstrated in partnership with Walgreens, AllazoHealth’s solution has been shown to advance health equity – proven to be even more effective for those patients in need of the most support based on the CDC Vulnerability Index.
Nomination Title: AllazoHealth
